BR0316126A - Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica - Google Patents
Combinação de compostos para o tratamento de leucemia linfocìtica crÈnicaInfo
- Publication number
- BR0316126A BR0316126A BR0316126-9A BR0316126A BR0316126A BR 0316126 A BR0316126 A BR 0316126A BR 0316126 A BR0316126 A BR 0316126A BR 0316126 A BR0316126 A BR 0316126A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- lymphocytic leukemia
- chronic lymphocytic
- treatment
- compounds
- Prior art date
Links
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 title abstract 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 title abstract 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 abstract 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 abstract 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 abstract 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 abstract 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 abstract 1
- 229960004630 chlorambucil Drugs 0.000 abstract 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 abstract 1
- 229950008249 chlornaphazine Drugs 0.000 abstract 1
- 229960001842 estramustine Drugs 0.000 abstract 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 abstract 1
- 229960004961 mechlorethamine Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229960004694 prednimustine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960000875 trofosfamide Drugs 0.000 abstract 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 abstract 1
- 229960001055 uracil mustard Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42548102P | 2002-11-12 | 2002-11-12 | |
| PCT/IB2003/005454 WO2004043466A1 (en) | 2002-11-12 | 2003-11-10 | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0316126A true BR0316126A (pt) | 2005-09-27 |
Family
ID=32312996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0316126-9A BR0316126A (pt) | 2002-11-12 | 2003-11-10 | Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20060122186A1 (enExample) |
| EP (1) | EP1578426B1 (enExample) |
| JP (1) | JP4854198B2 (enExample) |
| CN (1) | CN100475212C (enExample) |
| AT (1) | ATE468855T1 (enExample) |
| AU (1) | AU2003280191A1 (enExample) |
| BR (1) | BR0316126A (enExample) |
| CA (1) | CA2504665C (enExample) |
| DE (1) | DE60332762D1 (enExample) |
| ES (1) | ES2348140T3 (enExample) |
| WO (1) | WO2004043466A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100386115C (zh) * | 2004-10-14 | 2008-05-07 | 孔庆忠 | 一种抗癌药物组合物 |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| US8501818B2 (en) * | 2005-03-14 | 2013-08-06 | Ceptaris Therapeutics, Inc. | Stabilized compositions of alkylating agents and methods of using same |
| US20110039943A1 (en) * | 2005-03-14 | 2011-02-17 | Robert Alonso | Methods for treating skin disorders with topical nitrogen mustard compositions |
| WO2009082662A1 (en) | 2007-12-21 | 2009-07-02 | Novartis Ag | Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia |
| WO2009120493A2 (en) * | 2008-03-27 | 2009-10-01 | Yaupon Therapeutics, Inc | Stabilized compositions of alkylating agents and methods of using same |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| CN105997981A (zh) * | 2016-06-13 | 2016-10-12 | 崔坤峰 | 苯丁酸氮芥的药物组合物及其抗抑郁的医药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506257A (en) * | 1992-03-26 | 1996-04-09 | University Of British Columbia | Aminocyclohexylamides for antiarrhythmic and anaesthetic uses |
| CN1088777A (zh) * | 1992-12-18 | 1994-07-06 | 丛繁滋 | 用于癌病灶直接给药的化疗药物制剂的制备方法 |
| AU2003232115A1 (en) * | 2002-05-13 | 2003-11-11 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
-
2003
- 2003-11-10 JP JP2004551110A patent/JP4854198B2/ja not_active Expired - Fee Related
- 2003-11-10 US US10/534,573 patent/US20060122186A1/en not_active Abandoned
- 2003-11-10 CA CA2504665A patent/CA2504665C/en not_active Expired - Fee Related
- 2003-11-10 DE DE60332762T patent/DE60332762D1/de not_active Expired - Lifetime
- 2003-11-10 AT AT03772561T patent/ATE468855T1/de not_active IP Right Cessation
- 2003-11-10 BR BR0316126-9A patent/BR0316126A/pt not_active IP Right Cessation
- 2003-11-10 ES ES03772561T patent/ES2348140T3/es not_active Expired - Lifetime
- 2003-11-10 AU AU2003280191A patent/AU2003280191A1/en not_active Abandoned
- 2003-11-10 WO PCT/IB2003/005454 patent/WO2004043466A1/en not_active Ceased
- 2003-11-10 CN CNB2003801031558A patent/CN100475212C/zh not_active Expired - Fee Related
- 2003-11-10 EP EP03772561A patent/EP1578426B1/en not_active Expired - Lifetime
-
2009
- 2009-08-19 US US12/543,868 patent/US8492383B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4854198B2 (ja) | 2012-01-18 |
| CA2504665A1 (en) | 2004-05-27 |
| JP2006508118A (ja) | 2006-03-09 |
| ES2348140T3 (es) | 2010-11-30 |
| US20060122186A1 (en) | 2006-06-08 |
| WO2004043466A1 (en) | 2004-05-27 |
| ATE468855T1 (de) | 2010-06-15 |
| CA2504665C (en) | 2012-12-18 |
| AU2003280191A1 (en) | 2004-06-03 |
| CN100475212C (zh) | 2009-04-08 |
| CN1711090A (zh) | 2005-12-21 |
| EP1578426B1 (en) | 2010-05-26 |
| US20090312290A1 (en) | 2009-12-17 |
| US8492383B2 (en) | 2013-07-23 |
| EP1578426A1 (en) | 2005-09-28 |
| DE60332762D1 (de) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1332137T3 (da) | Behandling af gastrointestinale stromale tumorer | |
| MY128664A (en) | Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | |
| TWI347186B (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| BR0314112A (pt) | Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia | |
| BR0316126A (pt) | Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica | |
| PH12021550456A1 (en) | Crystalline forms of a quinazole compound and its hydrochloride salts | |
| DK1471916T3 (da) | Behandling af rheumatoid arthritis under anvendelse af imatinib | |
| DK1631291T3 (da) | Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes | |
| ATE386528T1 (de) | Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs | |
| BR0312242A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar | |
| AU2003209521A1 (en) | Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas | |
| WO2004026930A3 (en) | The method for reducing inflammation using sti-571 or its salt | |
| HK1097535A (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2281 DE 23/09/2014. |